Fight CRC Clinical Trial Finder
| NCT ID | Title | 阶段 | Date Added | 地点 | Prior IO Allowed | CRC-directed | Status | 药物 | 标签 |
|---|---|---|---|---|---|---|---|---|---|
| NCT ID NCT03577665 |
Title为结直肠癌肝转移患者提供治愈性质子束疗法 | 阶段
不适用
|
Date Added 2018-07-05 |
地点
大韩民国
|
Prior IO Allowed 是 |
CRC-directed 是 |
Status
招聘
|
药物 |
标签
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT03860272 |
TitleFc-Engineered Anti-CTLA-4 Monoclonal Antibody Botensilimab in Advanced Cancer | 阶段
第 1 阶段
|
Date Added 2019-03-01 |
地点
Arizona, United States
California, United States Colorado, United States Connecticut, United States Florida, United States Massachusetts, United States New York, United States Oregon, United States Texas, United States 英国 |
Prior IO Allowed 是 |
CRC-directed 是 |
Status
活跃，非招募
|
药物
Balstilimab, Botensilimab |
标签
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT05973487 |
TitleA Basket Study of Customized Autologous TCR-T Cell Therapies in Patients With Locally Advanced (Unresectable) or Metastatic Solid Tumors | 阶段
第 1 阶段
|
Date Added 2023-08-03 |
地点
Arizona, United States
California, United States Connecticut, United States Florida, United States Illinois, United States Kentucky, United States Michigan, United States Minnesota, United States New York, United States North Carolina, United States Ohio, United States Oklahoma, United States Oregon, United States Pennsylvania, United States Tennessee, United States Texas, United States |
Prior IO Allowed 是 |
CRC-directed 是 |
Status
招聘
|
药物 |
标签
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT05976906 |
TitleUniversal Dual-target NKG2D-NKp44 CAR-T Cells in Advanced Solid Tumors | 阶段
第 1 阶段
|
Date Added 2023-08-04 |
地点
中国
|
Prior IO Allowed 是 |
CRC-directed 是 |
Status
招聘
|
药物 |
标签
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT05783089 |
TitleMSLN-targeted CAR-T Cells in Solid Tumors. | 阶段
第 1 阶段
|
Date Added 2023-03-24 |
地点 |
Prior IO Allowed 是 |
CRC-directed 是 |
Status
尚未招聘
|
药物 |
标签
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT05785325 |
TitleRC48-ADC 联合贝伐单抗治疗 HER2 阳性晚期结直肠癌 | 阶段
第二阶段
|
Date Added 2023-03-27 |
地点
中国
|
Prior IO Allowed 是 |
CRC-directed 是 |
Status
招聘
|
药物
RC48-ADC 加贝伐单抗 |
标签
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT05798533 |
TitleNeo-T in Treating Patients With Advanced Solid Tumors(GI-NeoT-03) | 阶段
第 1 阶段
|
Date Added 2023-04-04 |
地点
中国
|
Prior IO Allowed 是 |
CRC-directed 是 |
Status
招聘
|
药物
Cyclophosphamide, Fludarabine, Interleukin-2 |
标签
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT05799443 |
TitleEfficacy and Safety of SBRT Followed by Tislelizumab Plus Cetuximab and Irinotecan in Patients With Previously Treated RAS Wild-type Advanced Refractory Colorectal Cancer | 阶段
第二阶段
|
Date Added 2023-04-05 |
地点 |
Prior IO Allowed 是 |
CRC-directed 是 |
Status
尚未招聘
|
药物
cetuximab, Irinotecan Hydrochloride, Tislelizumab |
标签
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT00001823 |
TitleEvaluation for NCI Surgery Branch Immunotherapy Clinical Research Protocols | 阶段 |
Date Added 1999-11-04 |
地点
Maryland, United States
|
Prior IO Allowed 是 |
CRC-directed 是 |
Status
招聘
|
药物 |
标签
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT05382741 |
Title无病变证据 (NED) 的 IV 期结直肠癌患者的 Durvalumab 加瑞戈非尼辅助治疗与未治疗对照组对比：VIVA 试验 | 阶段
第二阶段
|
Date Added 2022-05-19 |
地点
意大利
|
Prior IO Allowed 是 |
CRC-directed 是 |
Status
招聘
|
药物
Durvalumab Injection for intravenous use 500 mg vial solution for infusion, Regorafenib 30 mg capsules, Imfinzi, Stivarga |
标签
MSS/ MMRp
|
